Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation

被引：83

作者：

Lee, Lois S. ^{[2
]}

Kinzig-Schippers, Martina ^{[3
]}

Nafziger, Anne N. ^{[1
]}

Ma, Lei ^{[4
]}

Soergel, Fritz ^{[3
,5
]}

Jones, Ronald N. ^{[6
]}

Drusano, George L. ^{[4
]}

Bertino, Joseph S., Jr. ^{[1
]}

机构：

[1] Bertino Consulting, Schenectady, NY 12303 USA

[2] Bassett Healthcare, Cooperstown, NY 13326 USA

[3] Inst Biomed & Pharmaceut Res IBMP, Nurnberg, Germany

[4] Ordway Res Inst, Albany, NY 12203 USA

[5] Univ Duisburg Essen, Dept Pharmacol, Essen, Germany

[6] JMI Labs, Jones Grp, N Liberty, IA 52317 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2010年 / 68卷 / 03期

关键词：

Antimicrobial pharmacokinetics; Pharmacodynamics; Antibiotics; Carbapenems; PSEUDOMONAS-AERUGINOSA; PHARMACOKINETICS; IMIPENEM; SELECTION; MODELS;

D O I：

10.1016/j.diagmicrobio.2010.06.012

中图分类号：

R51 [传染病];

学科分类号：

100201 [内科学];

摘要：

Imipenem/cilastatin and meropenem are carbapenem antibiotics that are infused intravenously (IV) over 30 to 45 min. We evaluated probability of target attainment and cumulative probability of target attainment of 30-min and 3-h infusions for imipenem/cilastatin and meropenem. Eighteen healthy adults in a randomized, 4-phase, crossover study received 1000 mg of imipenem/cilastatin or meropenem as a single-dose IV over 30 min or 3 h. A population pharmacokinetics analysis using a 2-compartment IV infusion model was performed. Monte Carlo simulations using various dosage regimens at steady-state and 30-min and 3-h infusion rates were performed to evaluate the probabilities of attaining 20% (bacteriostatic), 30%, and 40% (maximum kill) time above the MIC. Three-hour infusions of imipenem/cilastatin and meropenem improved the cumulative probability of target attainment for a variety of populations of microorganisms compared to 30-min infusions. Prolonged infusions have the potential to optimize efficacy of imipenem/cilastatin and meropenem. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：251 / 258

页数：8

共 23 条

[1]

CRAIG WA, 2001, 41 INT C ANT AG CHEM

[2]

D'Argenio DZ., 1997, ADAPT II user's guide

[3]

Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion [J].